Pharmula Acquisition To Provide US Expansion Base For Jingxin
This article was originally published in PharmAsia News
Shanghai-listed Jingxin Pharmaceutical is aiming to tap into the US market for its growing formulations business through the majority acquisition of Pharmula, a US-based contract services firm. The Chinese manufacturer is looking to capitalize on its partners’ strength in R&D to facilitate its global expansion.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.